Thalidomide effective against refractory Crohn's disease

December 14, 1999

A study in the December issue of Gastroenterology shows that thalidomide, a drug that became infamous in the 1960s for causing thousands of severe birth defects, can be an effective short-term treatment for Crohn's disease, even for patients whose disease has not responded to other therapies.

All 14 of the patients who completed the 12-week study, performed at the University of Chicago Hospitals and at Sunnybrook Hospital in Toronto, responded to the treatment; almost two-thirds of those patients had a clinical remission. More than half of the patients began to improve within four weeks.

"We were impressed by the number of patients with truly difficult-to-manage Crohn's disease who responded to thalidomide and with the speed of the drug's effect in some of these patients," said Eli Ehrenpreis, M.D., assistant professor of clinical medicine at the University of Chicago and director of the study. "Our results suggest that thalidomide has a very potent effect on Crohn's disease and could play an important role as a steroid-sparing agent."

Crohn's disease is a chronic and often debilitating condition in which inflammation of the intestines leads to severe diarrhea, abdominal pain and weight loss. It affects an estimate 200,000 people in the United States, primarily young adults. About 30 percent of patients develop fistulas, small leaks from the intestine that can extend to the skin of the abdomen.

The study involved 22 patients with Crohn's disease that did not respond to anti-inflammatory medications and was resistant to treatment with steroids. Before beginning the study, nine patients had severe intestinal symptoms and 13 had perianal fistulas. Their median score on the Crohn's Disease Activity Index, a measure of disease severity, was 371. (CDAI scores range from 150, disease in remission, to 500.)

Fourteen of the 22 patients completed 12 weeks of treatment. All 14 had either a 150-point or greater reduction in disease activity or dramatic improvement of fistulas. Five patients had complete closure of their fistulas.

The median CDAI score improved from 371 at the trial's start, to 210 at four weeks, to 175 at 12 weeks. Three patients were able to stop taking steroids entirely and the median daily steroid dose fell more than 70 percent, from 26 mg down to 7.5 mg.

Although never approved for use in the United States, Thalidomide was widely used in the late 1950s and early 1960s in Europe, Canada and Japan, to treat nausea and sleeplessness in pregnant women suffering from morning sickness. Its use resulted in more than 10,000 severe birth defects, deformities of the limbs or internal organs in the exposed newborns.

In July of 1998, however, thalidomide won FDA approval for the treatment of leprosy. It has been tested recently against several other disorders, especially autoimmune diseases, because it is known to inhibit tumor necrosis factor (TNF), one component of the immune response. Two patients who did not respond to infliximab, an antibody directed at TNF that was recently approved for treating Crohn's disease, did respond to thalidomide therapy.

All patients in this study had to practice reliable birth control to prevent any risk of birth defects. Thalidomide has several side effects in addition to causing birth defects. All patients reported sleepiness and several dropped out of the study, primarily because of drowsiness. Others complained of a diffuse rash or constipation or had elevated blood pressure. Several patients had their doses reduced from 300 to 200 mg. per day down to as low as 100 to 50 mg. per day. The lower doses did not appear to reduce the drug's benefits.

The most serious concern was mild symptoms of peripheral neuropathy, a loss of sensation or discomfort in the hands and feet, reported by two patients in the study.

A smaller low-dose study, sponsored by the drug manufacturer (Celgene), was conducted at Cedars-Sinai Medical Center in Los Angeles and published in the same journal. Seven of the ten patients who completed this study responded to the drug; two had clinical remissions. All ten were able to reduce their steroid doses by at least 50 percent and two were able to discontinue steroid use.

"Together, these two small, open-label studies provide preliminary data that suggest a beneficial effect of thalidomide in Crohn's disease," wrote Drs. Bruce Sands and Daniel Podolsky from the Massachusetts General Hospital in an editorial accompanying the Gastroenterology articles.

"This drug must be carefully controlled and monitored, especially for use in women of childbearing age," notes Ehrenpreis, "but it would be unconscionable to withhold thalidomide from seriously ill patients if controlled trials confirm the safety and efficacy of this treatment in patients with refractory Crohn's disease."

A controlled clinical trial comparing the response to two different doses of thalidomide and placebo is being planned.

Funding for the Chicago study was provided by the Gastrointestinal Research Foundation, Chicago, and the University of Chicago's Clinical Research Center.

Additional authors of the study include Drs. Stephen Hanauer, Sunanda Kane and Russell Cohen of the University of Chicago Inflammatory Bowel Disease Center, and Lawrence Cohen of Sunnybrook Hospital, Toronto. The lower-dose study was directed by Eric Vasiliauskas, M.D. of Cedars-Sinai.
-end-


University of Chicago Medical Center

Related Birth Defects Articles from Brightsurf:

Assessing cancer diagnosis in children with birth defects
In this study, led by Baylor College of Medicine and Texas Children's Hospital, researchers provide a better understanding of cancer risk in children with birth defects.

Some antibiotics prescribed during pregnancy linked with birth defects
Children of mothers prescribed macrolide antibiotics during early pregnancy are at an increased risk of major birth defects, particularly heart defects, compared with children of mothers prescribed penicillin, finds a study published by The BMJ today.

Weight-loss surgery cuts risk of birth defects
Children born to women who underwent gastric bypass surgery before becoming pregnant had a lower risk of major birth defects than children born to women who had severe obesity at the start of their pregnancy.

Defective cilia linked to heart valve birth defects
Bicuspid aortic valve (BAV), the most common heart valve birth defect, is associated with genetic variation in human primary cilia during heart valve development, report Medical University of South Carolina researchers in Circulation.

Findings shed new light on why Zika causes birth defects in some pregnancies
A new study shows that the risk of giving birth to a child with microcephaly might be related to how the immune system reacts against the Zika virus -- specifically what kind of antibodies it produces.

Severe air pollution can cause birth defects, deaths
In a comprehensive study, researchers from Texas A&M University have determined that harmful particulate matter in the atmosphere can produce birth defects and even fatalities during pregnancy using the animal model.

Famous cancer-fighting gene also protects against birth defects
New research has revealed how the famous tumour suppressor gene p53 is surprisingly critical for development of the neural tube in female embryos.

Biomarkers may predict Zika-related birth defects
The highest risk of birth defects is from Zika virus infection during the first and second trimester.

After 60 years, scientists uncover how thalidomide produced birth defects
More than 60 years after the drug thalidomide caused birth defects in thousands of children whose mothers took the drug while pregnant, scientists at Dana-Farber Cancer Institute have solved a mystery that has lingered ever since the dangers of the drug first became apparent: how did the drug produce such severe fetal harm?

Antiepileptic drug induces birth defects in frogs
A common drug for treating epileptic seizures may lead to birth defects if used during pregnancy by interfering with glutamate signaling in earliest stages of nervous system development, finds a study in frogs published in JNeurosci.

Read More: Birth Defects News and Birth Defects Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.